Transcatheter aortic valve implantation (TAVI): Risky and costly

BMJ (Online)

Volumn 345, Issue 7868, 2012, Pages

  Van Brabandt, Hans ^a,b   Neyt, Mattias ^a   Hulstaert, Frank ^a  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^b Belgian Center for Evidence Based Medicine   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AORTA STENOSIS; ARTERY CALCIFICATION; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EUROPEAN UNION; EVIDENCE BASED NURSING; HEALTH CARE COST; HEART VALVE PROSTHESIS; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL ETHICS; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PATIENT SAFETY; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; STROKE; SURGICAL APPROACH; SURGICAL RISK; SURVIVAL RATE; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSIENT ISCHEMIC ATTACK; AORTA VALVE STENOSIS; DEVICE APPROVAL; ECONOMICS; HEART CATHETERIZATION; HEART VALVE REPLACEMENT; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

AORTIC VALVE STENOSIS; COST-BENEFIT ANALYSIS; DEVICE APPROVAL; HEART CATHETERIZATION; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84864530669     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e4710     Document Type: Article

References (26)

1. Nainggolan L. Germany tops TAVI table, but room for growth remains, 1 November, 2011. www.theheart.org/coverages.do.
2. Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J 2005;26:2714-20. (Pubitemid 41746694)
3. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Survival in elderly patients with severe aortic stenosis is dramatically improved by aortic valve replacement: results from a cohort of 277 patients aged ≥80 years. Eur J Cardiothorac Surg 2006;30:722-7. (Pubitemid 44574533)
4. Ray S. Estimated population need for TAVI, data presented at a consensus meeting, 16 December 2008. www.ucl.ac.uk/nicor/audits/tavi/pdfs/estimated.
5. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4. (Pubitemid 27116107)
6. Cortez M. Edwards valve study may spur patient demand doctors aren't ready to meet Bloomberg News 2011 Apr 4. www.bloomberg.com/news/2011-04-04/ edwards-valve-study-may-spur-patient-demand-doctors-aren-t-ready-to-meet.html.
7. TAVI numbers rise in Europe as reimbursement, expertise expands. Heartwire 2012 May 17. www.theheart.org/article/1401795.do.
8. Neyt M, Van Brabandt H, Van de Sande S, Devriese S. Transcatheter aortic valve implantation (TAVI): a health technology assessment update. KCE reports 163C. Belgian Health Care Knowledge Centre (KCE), 2011.
9. NICE. Transcatheter aortic valve implantation for aortic stenosis. NICE interventional procedure guidance 421. NICE, 2012.
10. FDA. Edwards SAPIENTM transcatheter heart valve, model 9000TFX, sizes 23mm and 26mm and accessories. www.accessdata.fda.gov/cdrh-docs/pdf10/p100041a. pdf.
11. Wood S. Approve Sapien TAVR for high-risk operable patients, FDA advisors say. Heartwire 2012 Jun 14. www.theheart.org/article/1414539.do.
12. Hirschler B. EU medicines head urges tougher implant rules. 2012 www.reuters.com/ article/2012/01/06/us-breastimplants-ema-idUSTRE8050VL20120106.
13. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-98.
14. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-607.
15. FDA. SAPIEN THV briefing document - advisory committee meeting. FDA, 2011:301.
16. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 2012;366:1696-704.
17. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686-95.
18. Medicine in conflict. Businessweek 2006 Oct 23. www.businessweek.com/ magazine/ content/06-43/b4006081.htm.
19. FDA. FDA executive summary: Edwards SAPIEN THV. FDA, 2011.
20. Blackman D. Outcome of TAVI by valve type and access route: UK TAVI registry. 2011. www.pcronline.com/Lectures/2011/Outcome-of-TAVI-by-valve-type- and-access-route.- UK-TAVI-registry.
21. Gilard M. FRANCE II - French aortic national core valve and Edwards registry. EuroPCR conference, Paris, 17-20 May 2011.
22. British Cardiovascular Intervention Society, Society of Cardiothoracic Surgeons. Transcatheter aortic valve implantation (TAVI): a position statement. www.ucl.ac.uk/nicor/ audits/tavi/pdfs/bcisposition.
23. Nielsen HH, Klaaborg KE, Nissen H, Terp K, Mortensen PE, Kjeldsen BJ, et al. A prospective, randomised trial of transapical transcatheter aortic valve implantation vs. surgical aortic valve replacement in operable elderly patients with aortic stenosis: the STACCATO trial. EuroIntervention 2012. May 14. [Epub ahead of print].
24. O'Riordan M. STACCATO; transapical TAVI in surgery-eligible patients stopped due to adverse events. Heartwire 2011 Nov 10. www.theheart.org/article/ 1307437.do.
25. Hulstaert F, Neyt M, Vinck I, Stordeur S, Huić M, Sauerland S, et al. The pre-market clinical evaluation of innovative high-risk medical devices. KCE Report 158C. D/2011/10.273/31. Belgian Health Care Knowledge Centre, 2011.
26. Neyt M, Van Brabandt H, Devriese S, Van De Sande S. A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population. BMJ Open 2012;2:e001032.